十二氢-1H-吩恶嗪 | 861338-53-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并恶嗪类
• 中文名称: 十二氢-1H-吩恶嗪
• 英文名称: dodecahydro-1H-phenoxazine
• 英文别名: dodecahydro-phenoxazine；Dodecahydro-phenoxazin；2,3,4,4a,5a,6,7,8,9,9a,10,10a-dodecahydro-1H-phenoxazine
• CAS: 861338-53-6
• 化学式: C₁₂H₂₁NO
• 分子量: 195.305
• InChiKey: FZAPDYSQLCFDBR-UHFFFAOYSA-N

物化性质

• 沸点：
  299.4±15.0 °C(Predicted)
• 密度：
  0.988±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  14
• 可旋转键数：
  0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  21.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  十二氢-1H-吩恶嗪 在 硫酸 、 sodium nitrite 作用下， 生成 10-nitroso-decahydro-phenoxazine
  参考文献：
  名称：

  Koetz; Merkel, Journal fur praktische Chemie (Leipzig 1954), 1926, vol. <2> 113, p. 74

  摘要：

  DOI：
• 作为产物：
  描述：

  1,2-环己二醇 在 bis[dichloro(pentamethylcyclopentadienyl)iridium(III)] 、 氟硼酸铵 、 三氟乙酸 作用下， 以 均三甲苯 为溶剂， 反应 18.0h， 以63%的产率得到十二氢-1H-吩恶嗪
  参考文献：
  名称：

  胺和邻二醇的铱催化缩合生成取代哌嗪

  摘要：

  描述了从胺和 1,2-二醇合成哌嗪的简单程序。杂环化由 [Cp*IrCl2]2 和碳酸氢钠催化，可以用甲苯或水作为溶剂来实现。该转化不需要任何化学计量添加剂，只产生水作为副产品。该反应可以在 1,2-二胺和 1,2-二醇之间或通过伯烷基胺和 1,2-二醇之间的双缩合进行。哌嗪环上至少需要一个取代基才能以良好的收率实现环化。该机制被认为涉及 1,2-二醇脱氢为 α-羟基醛，后者与胺缩合形成 α-羟基亚胺。后者重排为相应的α-氨基羰基化合物，

  DOI：

  10.1002/ejoc.201201099

文献信息

• TERTIARY AMINE COMPOUND OR IMINE COMPOUND-POLYMER CONJUGATE AND PRODUCTION METHOD THEREFOR
  申请人：Seikagaku Corporation

  公开号：US20200138964A1

  公开（公告）日：2020-05-07

  Provided is a compound obtained by conjugating a tertiary amine compound or imine compound, which is useful as a drug, with a polymer, in which a structure D + having a quaternary ammonium salt or iminium salt formed from a tertiary amine compound or imine compound D and a polymer residue Poly having a carboxy group are bonded to each other via a structure —C(R 1 )(R 2 )OC(O)ANHC(═O)—.

  提供的是一种化合物，通过将一种三级胺化合物或亚胺化合物与聚合物共轭，用作药物，其中具有由三级胺化合物或亚胺化合物D形成的季铵盐或亚胺盐的结构D + 和具有羧基的聚合物残基Poly通过结构—C(R 1 )(R 2 )OC(O)ANHC(═O)—相互键合。
• PRIMARY AMINE COMPOUND OR SECONDARY AMINE COMPOUND-ACIDIC POLYSACCHARIDE CONJUGATE AND PRODUCTION METHOD THEREFOR
  申请人：Seikagaku Corporation

  公开号：US20220040318A1

  公开（公告）日：2022-02-10

  Provided is a novel conjugate of a primary or secondary amine compound with an acidic polysaccharide, which is a compound represented by Formula (I) or a pharmaceutically acceptable salt thereof, where in Formula (I), D, R 1 , R 2 , A, and Poly are as defined in the specification.

  提供的是一种主要或次要胺化合物与酸性多糖结合的新型共轭物，该化合物由式（I）表示或其药用盐，其中在式（I）中，D、R1、R2、A 和 Poly 如规范中定义。
• NITROGENOUS HETEROCYCLIC COMPOUND AND MEDICINAL USE THEREOF
  申请人：Ochiai Hiroshi

  公开号：US20090233908A1

  公开（公告）日：2009-09-17

  A compound represented by formula (I): (wherein the symbols are the same as defined in the description), a salt thereof, an N-oxide thereof, a solvate thereof or a prodrug thereof, and medicinal use thereof. The compound represented by formula (I) has CXCR4 antagonistic activity. It is hence useful as, e.g., a preventive and/or therapeutic agent for CXCR4-mediated diseases such as inflammatory/immunologic diseases (e.g., rheumatoid arthritis, arthritis, retinopathy, pulmonary fibrosis, and rejection reactions of transplanted organs), allergic diseases, infections diseases (e.g., human immunodeficiency virus infection and acquired immunologic deficiency syndrome), psychoneurotic diseases, cerebral diseases, cardiac/vascular disease, metabolic diseases, cancer diseases (e.g., cancer, cancer metastasis) or as an agent for regeneration therapy.

  化合物的化学式为（I）：（其中符号的定义与说明书中相同），其盐，N-氧化物，溶剂化合物或前药，以及其药用。化合物（I）具有CXCR4拮抗活性。因此，它可用作预防和/或治疗CXCR4介导疾病的药物，例如炎症/免疫疾病（例如类风湿性关节炎，关节炎，视网膜病变，肺纤维化和移植器官的排斥反应），过敏性疾病，感染性疾病（例如人类免疫缺陷病毒感染和获得性免疫缺陷综合症），心理神经疾病，脑部疾病，心血管疾病，代谢性疾病，癌症（例如癌症，癌症转移）或再生治疗剂。
• Azetidine ring compounds and drugs comprising the same
  申请人：Habashita Hiromu

  公开号：US20070135402A1

  公开（公告）日：2007-06-14

  It is intended to provide compounds having EDG-5 antagonism. Because of having EDG-5 antagonism, compounds of the formula (I): wherein each symbol is as defined in the description; salts thereof, N-oxides thereof, solvates thereof or prodrugs thereof are useful as preventive and/or therapeutic agent for EDG-5 mediated diseases, for example, diseases caused by blood vessel contraction (e.g. cerebrovascular spasms disease, cardiovascular spasms diseases, coronary artery spasms disease, hypertension, pulmonary hypertension, renal diseases, myocardial infarction, angina pectoris, arrhythmia, portal hypertension, varicosity and the like), arteriosclerosis, pulmonary fibrosis, hepatic fibrosis, renal fibrosis, respiratory diseases (e.g. bronchial asthma, chronic obstructive pulmonary diseases and the like), nephropathy, diabetes, hyperlipemia and the like.

  本发明旨在提供具有EDG-5拮抗作用的化合物。由于具有EDG-5拮抗作用，式（I）中的化合物：其中每个符号如描述中所定义的，其盐，N-氧化物，溶剂化物或其前药，可用作预防和/或治疗EDG-5介导的疾病的药物，例如血管收缩引起的疾病（例如脑血管痉挛疾病，心血管痉挛疾病，冠状动脉痉挛疾病，高血压，肺动脉高压，肾脏疾病，心肌梗死，心绞痛，心律失常，门脉高压，静脉曲张等），动脉硬化，肺纤维化，肝纤维化，肾脏疾病（例如肾病，糖尿病，高脂血症等）和其他疾病。
• Nitrogen-containing heterocyclic compounds and medicinal use thereof
  申请人：Habashita Hiromu

  公开号：US20070167459A1

  公开（公告）日：2007-07-19

  The compound represented by formulae (I) and (II), the salt thereof, the N-oxide thereof or the solvate thereof, or the prodrug thereof and the pharmaceutical composition comprising thereof have a CXCR4-regulating effect, and they are effective in treatment and prevention of various inflammatory disease, various allergic disease, acquired immunodeficiency syndrome infection with human immunodeficiency virus, or agents for regeneration therapy. (wherein ring A represents a nitrogen-containing heterocyclic group which may have a substituent(s); ring B represents a homocyclic group which may have a substituent(s) or a heterocyclic group which may have a substituent(s); and Y represents a hydrocarbon group which may have a substituent(s), a heterocyclic group which may have a substituent(s), an amino group which may be protected, a hydroxyl group which may be protected or a mercapto group which may be protected; T represents ring A or an amino group which may be protected.)

  式(I)和(II)所代表的化合物、其盐、N-氧化物或溶剂合物、或其前药，以及包含它们的制药组合物具有CXCR4调节作用，它们对各种炎症性疾病、各种过敏性疾病、艾滋病毒感染、或再生治疗剂具有治疗和预防作用。(其中环A代表可能具有取代基的含氮杂环基团；环B代表可能具有取代基的同环基团或可能具有取代基的杂环基团；Y代表可能具有取代基的碳氢基团、可能具有取代基的杂环基团、可能被保护的氨基、可能被保护的羟基或可能被保护的巯基；T代表环A或可能被保护的氨基。)